An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer.
In just a few years’ time, Ipilumumab could be approved as a treatment for the world’s third-most common type of cancer.
The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. These are the words of a core statement from a study, recently published in the highly respected journal “The Lancet Oncology”, which was set up based on collaboration between the world’s leading centres for the research and treatment of prostate cancer.
The scientists investigated the extent to which immunotherapy with this agent is also suitable for the more common type of advanced prostate cancer. The medication is already being successfully used as immunotherapy for advanced melanoma – a comparatively rare type of cancer.
Read more . . .
The Latest on: Immunotherapy
[google_news title=”” keyword=”Immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapy
- Health Spotlight: Immunotherapy helps kidney cancer patients live longeron March 18, 2024 at 5:38 pm
(WISH) — Kidney cancer is among the 10 most common cancers in both men and women. About 81,000 people will be diagnosed with it this year. A decade ago, advanced kidney cancer was a death sentence.
- AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remainon March 18, 2024 at 4:05 am
And AstraZeneca, utilizing a similar immunotherapy strategy, has also come up with a rivaling update as it awaits an FDA decision. For GSK, Jemperli plus chemotherapy showed a “clinically meaningful ...
- Rethinking Immunotherapy for Cancer: When Is the Best Time to Stop?on March 17, 2024 at 11:00 am
Spread the loveImmunotherapy has revolutionized the treatment of cancer, offering hope to many patients whose cancers were once considered untreatable. However, as research advances, an important ...
- Cancer patients won't need to leave for B.C. for new immunotherapy treatmenton March 17, 2024 at 4:00 am
Starting this month, 20 adults and five children with lymphoma and some forms of leukemia who haven’t had success with other treatments will get immunotherapy treatment in Vancouver ...
- Researchers find link between gut bacteria and the success of milk-allergy oral immunotherapyon March 14, 2024 at 11:32 pm
Researchers led by Hiroshi Ohno at the RIKEN Center for Integrative Medical Sciences in Japan have discovered a link between gut bacteria and the success of milk-allergy oral immunotherapy.
- Bringing Immunotherapy Straight to the Sourceon March 13, 2024 at 5:01 pm
In cancer immunotherapy, T cells are often the stars of the show. Many immune checkpoint blockade drugs keep cancer cells from evading T cells, and cellular immunotherapies arm T cells with chimeric ...
- No Benefit to Adding Chemo to Immunotherapy in Older Adults With NSCLCon March 12, 2024 at 5:00 pm
Adding chemotherapy to immunotherapy increased the adverse event burden without improving survival outcomes compared with immunotherapy alone in older adults with NSCLC.
- Meta-Analysis Challenges the Role of Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: 'Less is More,' Says Researcherson March 11, 2024 at 12:09 pm
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.
- Tapping Into Immunotherapy’s Potential to Help More Peopleon March 8, 2024 at 12:02 pm
Discover what researchers have learned about varying immunotherapy response rates between patients with the same cancer types.
- Diagnosed with stage 4 kidney cancer, a woman is disease-free after immunotherapyon March 7, 2024 at 11:50 pm
A stage 4 kidney cancer diagnosis was no match for a potent blend of immunotherapy, including a unique approach to reduced-frequency dosing.
via Bing News